PACTR202003767867253
Recruiting
Phase 1
A Phase I Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of a Human Monoclonal Antibody, CAP256V2LS (VRC-HIVMAB0102-00-AB) administered intravenously to HIV-negative and HIV-positive women or subcutaneously alone and in combination with VRC07- 523LS and /or PGT121 to HIV-negative women in South Africa
CAPRISA0 sites76 target enrollmentFebruary 5, 2020
ConditionsHIV/AIDS
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- HIV/AIDS
- Sponsor
- CAPRISA
- Enrollment
- 76
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 to 45 years of age
- •Born female
- •Able and willing to complete the informed consent process
- •Able to understand the information provided, including the potential impact and/or risks linked to IV and SC administration of the study product, willing to comply with protocol procedures, has access to the clinical research site and is available for follow\-up for the study duration
- •Based on clinical assessment, participant must be in good general health as per opinion of the Principal Investigator (PI) or designee
- •Haemoglobin \> 10g/dl
- •Neutrophil count within institutional normal range/accompanied by the PI/designee approval
- •Platelets within institutional normal range/ accompanied by the PI/designee approval
- •Creatinine \< 1\.1 x ULN
- •ALT \< 1\.25 x ULN
Exclusion Criteria
- •Any clinically significant acute or chronic medical condition that in the opinion of the PI/designee makes the participant unsuitable for participation in the study, or jeopardises the safety or rights of the participant
- •If planning a pregnancy for the duration of the study, currently pregnant or breastfeeding
- •Exceeding the weight of 95 kilograms
- •A history of alcohol or substance use judged by the PI to potentially interfere with participant study compliance
- •Prior participation in an investigational HIV vaccine trial, except if proof of allocation to the placebo arm is available
- •Administration of a mAb or polyclonal immunoglobulin within 28 days prior to enrolment
- •Any history of anaphylaxis and related symptoms such as hives, respiratory difficulty, or angioedema
- •Evidence of autoimmune disease or currently receiving immunosuppressive therapy
- •Participants in the study may not take part in other concurrent research studies that would interfere with the objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A Phase 1 Study for patients with advanced solid tumors.CTRI/2011/12/002225Orchid Research Laboratories Ltd36
Completed
Not Applicable
A Phase I, Dose Escalation Study on the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) and its Comparability to NovoSeven® in Healthy Male Volunteers Pre-Treated with Fondaparinuxhaemophilia10064477NL-OMON34613Centre for Human Drug Research36
Completed
Phase 1
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38
Unknown
Phase 1
A Phase 1, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Hormone Therapy-Resistant Prostate Cancer SubjectsProstate cancerJPRN-jRCT2080220970Takeda Pharmaceutical Company Limited
Withdrawn
Phase 1
EOSTeM (NEOnatal STroke Mesenchymal Stem Cell) Trial: Assessing the Safety of Mesenchymal Stem Cells for Babies with StrokeTerm/near term neonatal strokeNeurological - Other neurological disordersStroke - IschaemicReproductive Health and Childbirth - Complications of newbornACTRN12624000145505Sydney Children's Hospital Network12